Oncology News

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm - 4pm CET in Madrid, Spain. The session, titled “Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy,” will be co-chaired by Rafael Duarte, MD, PhD, Hospital Universitario Puerta de Hierro Majadahonda, and Mohamad Mohty, MD, PhD, Hôp...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)...

ORLANDO, Fla.--(BUSINESS WIRE)--Imaginostics, Inc. today announced that it has received a Letter of Support from Siemens Healthineers in connection with ongoing exploratory discussions regarding potential collaboration in quantitative MRI and imaging biomarkers. As part of these discussions, Imaginostics and Siemens Healthineers intend to continue dialogue concerning potential technical and commercial pathways for Imaginostics’ envisioned ImagiView™ and ImagiSight™ offerings and their potential...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People’s Republic of China has granted regulatory approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln). The approval establishes ANKTIVA’s initial presence in Asia and reflects the Company’s strategy to expand global access through reliance-based regulatory pathways. In Macau, ANKTIVA is approved in co...

NEW DELHI--(BUSINESS WIRE)--Fortis Healthcare has been honored with six prestigious awards at the FICCI Advantage Healthcare India, International Summit on Medical Value Travel....

WILMINGTON, Del.--(BUSINESS WIRE)--Synnovation Therapeutics, LLC (“Synnovation”), a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology today announced a definitive agreement for Novartis to acquire Pikavation Therapeutics, Inc. (“Pikavation”) and its portfolio of PI3Kα inhibitor programs, including SNV4818. Pikavation is a wholly-owned subsidiary of Synnovation. SNV4818 is a potentially best-in-class pan-mutant sele...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals announces that nadofaragene firadenovec-vncg (ADSTILADRIN ®) has been upgraded to a National Comprehensive Cancer Network® (NCCN®) Category 2A recommended option for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors (+Ta/T1) without carcinoma in situ (CIS) in the 2026 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).1 ADSTILADRIN is...

BOSTON & ALLENTOWN, Pa.--(BUSINESS WIRE)--Ibex Medical Analytics (Ibex), a leader in clinical-grade AI-powered pathology, today announced a strategic collaboration with HNL Lab Medicine, a leading multi-regional medical laboratory in the United States. Through this partnership, HNL Lab Medicine will deploy Ibex’s advanced AI solutions, Ibex Prostate for biopsies and transurethral resection of the prostate (TURP), to further enhance diagnostic accuracy and workflow efficiency. The deployment mar...

PALO ALTO, Calif.--(BUSINESS WIRE)--Siemens Healthineers announced that its Varian TrueBeam radiotherapy systems, which include TrueBeam, TrueBeam STx, VitalBeam, and Edge, have received FDA 510(k) clearance for the use of low-dose radiation therapy (LDRT) in adults with medically refractory osteoarthritis (OA). This clearance expands Varian’s radiotherapy systems beyond cancer care into chronic musculoskeletal conditions, bringing precision radiotherapy to millions of people living with persis...

DALLAS--(BUSINESS WIRE)--Massive Bio today announced the launch of NexusPulse™, a real-time AI signal engine that helps oncology organizations detect change earlier, prioritize the right next action, and accelerate testing, treatment, and trial access. Built within Reticulum Nexus™ and powered by SYNERGY-AI™, NexusPulse transforms consented real-world clinical and biomarker data into always-on analytics and actionable intelligence. NexusPulse is the heartbeat of real-world oncology markets. It...